|
|
阿帕替尼在肝细胞癌治疗中的临床研究进展
|
Abstract:
肝细胞癌是临床常见的恶性肿瘤，严重影响人民的身体健康，因其发病隐匿，大多数患者确诊时已是中晚期，丧失手术机会，靶向药物治疗作为中晚期肝细胞癌的主要治疗策略，已广泛应用于临床。以往用于治疗肝细胞癌的一线靶向药物有索拉菲尼、仑伐替尼，阿帕替尼作为新型的口服小分子抗血管生成药物，近年来在对肝细胞癌的治疗中取得了较好的疗效，成为了治疗肝细胞癌的二线治疗。本文就阿帕替尼在肝细胞癌的作用机制、临床研究进展、药物不良反应等进行综述。
Hepatocellular carcinoma (HCC) is a common cancer in clinic, and HCC is one of the diseases that threaten the health and life of human. Because of its insidious onset, most patients are in the middle and late stages when they are diagnosed, and they have lost the opportunity for surgery. Targeted therapy is the main treatment strategy for advanced HCC in clinical practice. Sorafenib and lenvatinib are once the first-line therapeutic agent for HCC patients. In recent years, apatinib, which is an orally novel small-molecule anti-angiogenesis inhibitor, has shown good efficacy and has become the second-line drug in the treatment of HCC. This article reviews the mechanism, current research progress and adverse drug reaction of apatinib in HCC.
| [1] | 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版) [J]. 临床肝胆病杂志, 2020, 36(2): 277-292. |
| [2] | Park, J., Chen, M., Colombo, M., et al. (2015) Global Patterns of Hepatocellular Carcinoma Management from Diagnosis to Death: The BRIDGE Study. Liver International, 35, 2155-2166. https://doi.org/10.1111/liv.12818 |
| [3] | Peng, S., Zhang, Y., Peng, H., et al. (2016) Intracellular Autocrine VEGF Signaling Promotes EBDC Cell Proliferation, Which Can Be Inhibited by Apatinib. Cancer Letters, 373, 193-202. https://doi.org/10.1016/j.canlet.2016.01.015 |
| [4] | Han, Z., He, Z., Wang, C., et al. (2018) The Effect of Apatinib in the Treatment of Sorafenib Resistant Metastatic Hepatocellular Carcinoma. Medicine, 97, e13388. https://doi.org/10.1097/MD.0000000000013388 |
| [5] | Huang, A., Yang, X.R., Chung, W.Y., et al. (2020) Targeted Therapy for Hepatocellular Carcinoma. Signal Transduction and Targeted Therapy, 5, Article No. 146. https://doi.org/10.1038/s41392-020-00264-x |
| [6] | 中国医师协会肝癌专业委员会. 肝细胞癌分子靶向药物临床应用中国专家共识(2020版) [J]. 中华医学杂志, 2021, 101(28): 2185-2194. |
| [7] | Folkman, J. (1971) Tumor Angiogenesis: Therapeutic Implications. The New England Journal of Medicine, 285, 1182-1186. https://doi.org/10.1056/NEJM197111182852108 |
| [8] | Yang, C. and Qin, S. (2018) Apatinib Targets Both Tumor and Endothelial Cells in Hepatocellular Carcinoma. Cancer Medicine (Malden, MA), 7, 4570-4583. https://doi.org/10.1002/cam4.1664 |
| [9] | 赵灵颖, 张文青, 李存玺, 等. 阿帕替尼抗肿瘤作用机制研究进展[J]. 肿瘤防治研究, 2021,48(1): 7-11. |
| [10] | 朱丹, 赵宏伟, 赵健琦, 等. 肿瘤分子靶向药物阿帕替尼的临床研究进展[J]. 中国医院药学杂志, 2017, 37(2): 194-198. |
| [11] | Zhang, H. (2015) Apatinib for Molecular Targeted Therapy in Tumor. Drug Design, Development and Therapy, 9, 6075-6081. https://doi.org/10.2147/DDDT.S97235 |
| [12] | Li, J., Zhao, X., Chen, L., et al. (2010) Safety and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor YN968D1 in Patients with Advanced Malignancies. BMC Cancer, 10, Article No. 529.
https://doi.org/10.1186/1471-2407-10-529 |
| [13] | 刘春浩, 赵豪, 李小毅. 阿帕替尼的抗肿瘤机制研究进展[J]. 癌症进展, 2021, 19(2): 6. |
| [14] | Li, N.N., Zhou, F.J., Zhao, L., et al. (2019) Efficacy and Safety of Apatinib in Treating Advanced Colorectal Cancer. Acta Academiae Medicinae Sinicae, 41, 170-174. |
| [15] | Zheng, B., Ren, T., Huang, Y., et al. (2017) Apatinib Inhibits Migration and Invasion as Well as PD-L1 Expression in Osteosarcoma by Targeting STAT3. Biochemical & Biophysical Research Communications, 495, 1695-1701.
https://doi.org/10.1016/j.bbrc.2017.12.032 |
| [16] | Ma, X.X., Huang, H.B., Zhao, H.Y., et al. (2013) Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Research, 70, 7981-7991. |
| [17] | 柯少波, 汪晶, 邱虎, 等. 阿帕替尼一线治疗晚期肝癌疗效观察[J]. 肿瘤防治研究, 2021, 48(7): 723-726. |
| [18] | 闫其星, 唐文军, 卓曼云, 等. 甲磺酸阿帕替尼治疗晚期原发性肝癌的近期疗效观察[J]. 肿瘤药学, 2021, 11(4): 469-473. |
| [19] | Zhang, Y., Fan, W., Wang, Y., et al. (2019) Apatinib for Patients with Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. Cancer Control, 26.
https://doi.org/10.1177/1073274819872216 |
| [20] | Goldstein, R., Yu, D., Gillmore, R., et al. (2014) Oxaliplatin/5-Fluorouracil in Advanced Hepatocellular Carcinoma: Case Report and Single-Center Retrospective Review. Future Oncology, 10, 2007-2014.
https://doi.org/10.2217/fon.14.108 |
| [21] | Ogasawara, S., Chiba, T., Ooka, Y., et al. (2014) A Phase I/II Trial of Capecitabine Combined with Peginterferon α-2a in Patients with Sorafenib-Refractory Advanced Hepatocellular Carcinoma. Investigational New Drugs, 32, 762-768.
https://doi.org/10.1007/s10637-014-0097-2 |
| [22] | 陈德志, 陈巧辉, 陈惠萍, 等. 阿帕替尼在原发性肝癌治疗中的应用研究进展[J]. 中国药业, 2019, 28(12): 128. |
| [23] | Yang, Z., Chen, G., Cui, Y., et al. (2019) The Safety and Efficacy of TACE Combined with Apatinib on Patients with Advanced Hepatocellular Carcinoma: A Retrospective Study. Cancer Biology & Therapy, 20, 321-327.
https://doi.org/10.1080/15384047.2018.1529099 |
| [24] | Qiu, Z., Shen, L., Jiang, Y., et al. (2021) Transarterial Chemoembolization (TACE) Combined with Apatinib versus TACE Combined with Sorafenib in Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Study. Annals of Translational Medicine, 9. https://doi.org/10.21037/atm-20-5360 |
| [25] | 高福洋, 沈太伟, 张宏伟, 等. 射频消融术联合阿帕替尼治疗肝细胞癌复发患者的疗效及预后因素研究[J]. 中西医结合肝病杂志, 2021, 31(3): 219-222. |
| [26] | 曹钰. 射频消融术联合阿帕替尼治疗复发性小肝癌的临床研究[D]: [硕士学位论文]. 泸州: 西南医科大学, 2019. |
| [27] | 秦叔逵, 白玉贤, 欧阳学农, 等. 阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心II期临床试验[J]. 临床肿瘤学杂志, 2017, 22(12): 1057-1065. |
| [28] | 吴培生, 罗永香, 陈斯欢. 不同剂量阿帕替尼联合经动脉化疗栓塞治疗中晚期原发性肝癌的临床效果及安全性[J]. 广西医学, 2020, 42(3): 293-296. |
| [29] | 涂艳, 彭枫. 阿帕替尼治疗恶性肿瘤的临床研究进展[J]. 中国肿瘤临床, 2016, 43(12): 545-548. |
| [30] | 宋锦添, 陈奕贵, 许春伟, 等. 阿帕替尼治疗53例晚期原发性肝癌的疗效[J]. 临床与病理杂志, 2017, 37(3): 557-563. |
| [31] | Duffaud, F., Sleijfer, S., Litiere, S., et al. (2015) Hypertension (HTN) as a Potential Biomarker of Efficacy in Pazopanib-Treated Patients with Advanced Non-Adipocytic Soft Tissue Sarcoma. A Retrospective Study Based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 Trials. European Journal of Cancer, 51, 2615-2623. https://doi.org/10.1016/j.ejca.2015.08.002 |
| [32] | Liu, X., Qin, S., Wang, Z., et al. (2017) Early Presence of Anti-Angiogenesis-Related Adverse Events as a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: A Cohort Study. Journal of Hematology & Oncology, 10, Article No. 153. https://doi.org/10.1186/s13045-017-0521-0 |
